ESPR · CIK 1434868
What Esperion Therapeutics, Inc. told the SEC could break it.
Esperion's risks pinch from both ends of its single drug franchise. Its sales run through a handful of drug wholesalers — three customers accounted for about 98% of gross NEXLETOL/NEXLIZET sales and held roughly 98% of net product-sales receivables in 2025 — while on the supply side it owns no plants and depends on sole-source third-party manufacturers to make bempedoic acid and its bempedoic acid/ezetimibe tablet, risking commercial shortfalls. That narrow operation sits atop a $1.6 billion accumulated deficit and high-cost debt, including 5.75% 2030 convertible notes and a December 2025 loan at a 9.75% fixed rate. It also flags CMS's December 2025 GLOBE and GUARD proposals, which would tie federal drug reimbursement to international most-favored-nation benchmark prices.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Three customers = 98% of U.S. product sales / receivableshigh
Three customers (drug wholesalers) accounted for approximately 98% of gross NEXLETOL/NEXLIZET sales and held ~98% of net product-sales trade receivables in 2025 — extreme distributor concentration.
“As of December 31, 2025, three customers hold approximately 98 % of the Company's trade receivables associated with net product sales and accounted for approximately 98 % of gross sales of NEXLETOL and NEXLIZET in 2025.”
SEC filing →As of 2026
Sole-source dependency
- Sole-source third-party manufacturing of bempedoic acid / ezetimibehigh
Esperion owns no manufacturing facilities and relies on sole-source third-party suppliers to make and supply bempedoic acid and the bempedoic acid/ezetimibe tablet (including ezetimibe), risking shortfalls in commercial supply.
“We may rely on sole source third-party suppliers to manufacture and supply bempedoic acid, the bempedoic acid / ezetimibe combination tablet, or future drug candidates which may not be able to produce sufficient inventory to meet commercial demand in a cost-efficient, timely manner, or at all.”
SEC filing →As of 2026
Liquidity & debt
- Accumulated deficit and high-cost debtmedium
Esperion has a $1.6 billion accumulated deficit and carries 5.75% 2030 convertible notes plus a December 2025 Loan at a 9.75% fixed rate, with a Credit Agreement that may constrain financial flexibility.
“Our 2030 Notes, which were issued in December 2024, carry a fixed rate of 5.75%. Our Loan, which was issued in December 2025, carries a fixed interest rate of 9.75%.”
SEC filing →As of 2026
Regulatory & policy
- CMS Most-Favored-Nation drug-pricing proposals (GLOBE/GUARD)medium
CMS's December 2025 GLOBE (Part B) and GUARD (Part D) proposed rules would tie federal drug reimbursement to international MFN benchmark prices, potentially forcing rebates on Esperion's commercial products.
“On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Daiichi Sankyo Europe GmbH (DSE)
“the Company recognized collaboration revenue of $ 148.8 million, made up of payments related to royalty revenue from DSE and sales of bulk tablets and API to DSE pursuant to the supply agreement that was executed with DSE.”
Cited →HLS Therapeutics
“HLS will be responsible for commercialization, including reimbursement and marketing.”
Cited →CSL Seqirus
“For additional details on the DSE, Otsuka, DS, Neopharm, CSL Seqirus, and HLS agreements, see Note 3 to our audited financial statements appearing elsewhere in this Annual Report on Form 10-K.”
Cited →Neopharm
“For additional details on the DSE, Otsuka, DS, Neopharm, CSL Seqirus, and HLS agreements, see Note 3 to our audited financial statements appearing elsewhere in this Annual Report on Form 10-K.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch